Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2023-10-04

Clinical Trial Update: Fenfluramine in CDKL5 Deficiency Disorder (CDD) [Phase 2]

View source ↗

Summary

Phase 2 trial update for fenfluramine in CDKL5 deficiency disorder has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Fenfluramine (fenfluramine)

Snippet

Sponsor: NYU Langone Health | Conditions: CDD | Phase 2 | Status: COMPLETED | Results posted: 2023-10-04